Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA (ZX008) in Dravet Syndrome
pharmaceutical investing Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Alvopetro Announces Year End 2025 Financial Results, Q1 2026 Dividend of US$0.12/share, and Filing of our AIF
QIMC Reports Results from Hole 1 DDH-26-01 at West-Advocate Natural Hydrogen Project, Nova Scotia; R2G2(TM) Exploration Model Applied
